Oruka Therapeutics (ORKA) Change in Account Payables (2010 - 2026)

Oruka Therapeutics' Change in Account Payables history runs 17 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• On a quarterly basis, Change in Account Payables rose 157.54% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 143.62% increase from a year earlier, with the FY2025 full-year figure at -$6.0 million, down 199.85% from the prior year.
• Change in Account Payables improved to $3.0 million in Q1 2026 per ORKA's latest filing, from -$4.8 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $6.4 million in Q2 2025 and bottomed at -$5.2 million in Q1 2025.
• The 5-year median for Change in Account Payables is -$103000.0 (2022), against an average of $132294.1.
• Across the five-year window, Change in Account Payables sank 4216.67% in 2022 and jumped 18121.88% in 2024, its largest moves.
• Year by year, Change in Account Payables stood at -$259000.0 in 2022, then soared by 115.44% to $40000.0 in 2023, then surged by 10902.5% to $4.4 million in 2024, then plunged by 208.13% to -$4.8 million in 2025, then jumped by 162.93% to $3.0 million in 2026.
• Per Business Quant, the three latest ORKA Change in Account Payables figures stand at $3.0 million (Q1 2026), -$4.8 million (Q4 2025), and -$2.5 million (Q3 2025).